Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,383,249
  • Shares Outstanding, K 98,277
  • Annual Sales, $ 1,902 M
  • Annual Income, $ 235,240 K
  • EBIT $ -115 M
  • EBITDA $ -117 M
  • 60-Month Beta 0.45
  • Price/Sales 1.14
  • Price/Cash Flow 9.02
  • Price/Book 1.89

Options Overview Details

View History
  • Implied Volatility 157.91% ( +65.14%)
  • Historical Volatility 214.10%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 157.91% on 07/18/25
  • IV Low 32.18% on 01/22/25
  • Put/Call Vol Ratio 1.68
  • Today's Volume 134,360
  • Volume Avg (30-Day) 17,539
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 197,740
  • Open Int (30-Day) 169,778

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.17
  • Number of Estimates 8
  • High Estimate 0.98
  • Low Estimate -0.45
  • Prior Year 0.07
  • Growth Rate Est. (year over year) +142.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.81 +9.88%
on 07/18/25
22.86 -38.43%
on 07/17/25
-6.70 (-32.23%)
since 06/18/25
3-Month
12.81 +9.88%
on 07/18/25
64.80 -78.28%
on 05/05/25
-39.72 (-73.83%)
since 04/17/25
52-Week
12.81 +9.88%
on 07/18/25
150.48 -90.65%
on 07/29/24
-129.71 (-90.21%)
since 07/18/24

Most Recent Stories

More News
Sarepta Therapeutics Provides Statement on ELEVIDYS

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Shortly after 2:30 p.m. ET today, Sarepta received an...

SRPT : 14.07 (-35.94%)
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

LOS ANGELES , July 18, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:...

SRPT : 14.07 (-35.94%)
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , July 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta...

SRPT : 14.07 (-35.94%)
Stocks Finish Slightly Lower on Mixed Earnings Results

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. September E-mini...

CVS : 61.96 (-2.12%)
SRPT : 14.07 (-35.94%)
ALV : 112.08 (-4.02%)
IVZ : 19.92 (+15.28%)
$IUXX : 23,065.47 (-0.05%)
ELV : 277.09 (-8.38%)
UNH : 282.65 (-1.88%)
ZNU25 : 110-250s (+0.24%)
ABT : 123.67 (+2.62%)
ESU25 : 6,334.75s (-0.09%)
TLN : 328.63 (+24.48%)
$DOWI : 44,342.19 (-0.32%)
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ:...

SRPT : 14.07 (-35.94%)
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025 - Sarepta Therapeutics, Inc. (SRPT)

New York, New York--(Newsfile Corp. - July 18, 2025) - If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ: SRPT) investment and want to learn about a potential recovery under the federal...

SRPT : 14.07 (-35.94%)
Stocks Pressured by Weakness in Netflix and Health Insurers

The S&P 500 Index ($SPX ) (SPY ) today down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.15%. September E-mini S&P futures...

CVS : 61.96 (-2.12%)
SRPT : 14.07 (-35.94%)
ALV : 112.08 (-4.02%)
IVZ : 19.92 (+15.28%)
$IUXX : 23,065.47 (-0.05%)
ELV : 277.09 (-8.38%)
ZNU25 : 110-250s (+0.24%)
ABT : 123.67 (+2.62%)
ESU25 : 6,334.75s (-0.09%)
TLN : 328.63 (+24.48%)
$DOWI : 44,342.19 (-0.32%)
SPY : 627.58 (-0.07%)
Stocks See Support from Dovish Fed Official Comment

The S&P 500 Index ($SPX ) (SPY ) today is up +0.18%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.17%. September E-mini S&P futures...

NFLX : 1,209.24 (-5.10%)
IBKR : 64.05 (+7.77%)
SRPT : 14.07 (-35.94%)
$SPX : 6,296.79 (-0.01%)
SYM : 54.54 (+0.66%)
ALV : 112.08 (-4.02%)
MMM : 153.23 (-3.65%)
$IUXX : 23,065.47 (-0.05%)
NQU25 : 23,224.25s (-0.12%)
ELV : 277.09 (-8.38%)
QQQ : 561.26 (-0.10%)
ZNU25 : 110-250s (+0.24%)
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders

NEW YORK , July 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities...

SRPT : 14.07 (-35.94%)
SRPT INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

SAN DIEGO , July 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics,...

SRPT : 14.07 (-35.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 24.27
2nd Resistance Point 21.73
1st Resistance Point 17.90
Last Price 14.07
1st Support Level 11.53
2nd Support Level 8.99
3rd Support Level 5.16

See More

52-Week High 150.48
Fibonacci 61.8% 97.89
Fibonacci 50% 81.64
Fibonacci 38.2% 65.40
Last Price 14.07
52-Week Low 12.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar